RNA (Avidity Biosciences, Inc.) Stock Financials & Earnings | Market Cap Arena

RNA (Avidity Biosciences, Inc.) Stock Financials & Earnings | Market Cap Arena

RNAAvidity Biosciences, Inc.

Mkt Cap$2B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$19M

Net Income (TTM)-$685M

EPS (TTM)-$4.97

Free Cash Flow (TTM)-$667M

Gross Margin-644.4%

Op. Margin-3977.3%

Net Margin-3650.4%

FCF Margin-3556.0%

P/S Ratio (TTM)123.6x

P/E Ratio (TTM)—

YoY Rev Growth+72.1%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$2M	-$46M	-$58M
Q2 23	$2M	-$40M	-$53M
Q3 23	$3M	-$45M	-$59M
Q4 23	$2M	$2M	-$67M
Q1 24	$4M	$3M	-$77M
Q2 24	$2M	$1M	-$83M
Q3 24	$2M	$2M	-$98M
Q4 24	$3M	$3M	-$121M
Q1 25	$2M	$2M	-$132M
Q2 25	$4M	-$134M	-$171M
Q3 25	$12M	$12M	-$189M
Q4 25	$860K	-$636K	-$254M

Valuation

Quarter	P/S	P/E
Q1 23	239.8x	—
Q2 23	236.4x	—
Q3 23	228.6x	—
Q4 23	242.4x	—
Q1 24	213.2x	—
Q2 24	218.6x	—
Q3 24	229.0x	—
Q4 24	212.6x	—
Q1 25	259.6x	—
Q2 25	216.0x	—
Q3 25	111.0x	—
Q4 25	123.6x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$49M	-$51M
Q2 23	-$50M	-$50M
Q3 23	-$37M	-$38M
Q4 23	$17M	$16M
Q1 24	-$70M	-$71M
Q2 24	-$65M	-$66M
Q3 24	-$66M	-$67M
Q4 24	-$100M	-$104M
Q1 25	-$125M	-$129M
Q2 25	-$200M	-$203M
Q3 25	-$156M	-$160M
Q4 25	-$170M	-$175M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$2M
Q2 23	$622K
Q3 23	$923K
Q4 23	$863K
Q1 24	$915K
Q2 24	$531K
Q3 24	$2M
Q4 24	$4M
Q1 25	$4M
Q2 25	$3M
Q3 25	$4M
Q4 25	$6M

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	+24.4%	+65.0%
Q2 23	+6.3%	+13.4%
Q3 23	+13.5%	+29.6%
Q4 23	-20.8%	+23.1%
Q1 24	+58.7%	+34.9%
Q2 24	-11.7%	+54.1%
Q3 24	-17.1%	+63.5%
Q4 24	+35.6%	+79.8%
Q1 25	-55.6%	+64.9%
Q2 25	+88.1%	+106.7%
Q3 25	+434.0%	+100.3%
Q4 25	-71.1%	+106.0%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$9M	407.7%
Q2 23	$9M	408.2%
Q3 23	$10M	348.5%
Q4 23	$10M	448.9%
Q1 24	$10M	290.9%
Q2 24	$13M	626.5%
Q3 24	$14M	603.3%
Q4 24	$14M	476.1%
Q1 25	$18M	1127.5%
Q2 25	$18M	459.0%
Q3 25	$19M	152.5%
Q4 25	$43M	5048.7%

OpEx Breakdown

Quarter	R&D	G&A
Q1 23	$48M	$12M
Q2 23	$43M	$12M
Q3 23	$48M	$14M
Q4 23	$53M	$16M
Q1 24	$67M	$14M
Q2 24	$64M	$21M
Q3 24	$77M	$23M
Q4 24	$96M	$28M
Q1 25	$99M	$34M
Q2 25	$138M	$37M
Q3 25	$155M	$46M
Q4 25	$167M	$89M

Revenue Segments

Quarter	Reportable Segment
Q1 25	$2M
Q2 25	$4M
Q3 25	$12M
Q4 25	$860K

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$119M	$468M	$586M
Q2 23	$154M	$423M	$577M
Q3 23	$86M	$457M	$543M
Q4 23	$185M	$410M	$595M
Q1 24	$471M	$444M	$916M
Q2 24	$576M	$723M	$1.3B
Q3 24	$370M	$1.2B	$1.6B
Q4 24	$220M	$1.3B	$1.5B
Q1 25	$254M	$1.1B	$1.4B
Q2 25	$244M	$939M	$1.2B
Q3 25	$350M	$1.5B	$1.9B
Q4 25	$383M	$1.3B	$1.7B

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	70M	+22.9%
Q2 23	71M	+1.4%
Q3 23	74M	+3.8%
Q4 23	76M	+2.6%
Q1 24	87M	+14.7%
Q2 24	107M	+22.6%
Q3 24	123M	+15.4%
Q4 24	128M	+4.2%
Q1 25	129M	+0.6%
Q2 25	130M	+0.3%
Q3 25	138M	+6.4%
Q4 25	138M	-0.1%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 18	—	—
FY 19	—	—
FY 20	$83K	82
FY 21	$75K	125
FY 22	$50K	186
FY 23	$38K	253
FY 24	$28K	391
FY 25	$37K	511